The lack of an effective treatment for Alzheimer'disease (AD), an increasing prevalence and
severe neurodegenerative pathology boost medicinal chemists to look for new drugs …

Dual binding site acetylcholinesterase inhibitors have recently emerged as a new class of
anti-Alzheimer agents with potential to positively modify the course of the disease. These …

Inspired by the structures of donepezil and rivastigmine, a novel series of indanone–
carbamate hybrids was synthesized using the pharmacophore hybridization‐based design …

Two novel families of dual binding site acetylcholinesterase (AChE) inhibitors have been
developed, consisting of a tacrine or 6-chlorotacrine unit as the active site interacting moiety …

New dual binding site acetylcholinesterase (AChE) inhibitors have been designed and
synthesized as new potent drugs that may simultaneously alleviate cognitive deficits and …

Alzheimer's disease (AD) is the most common form of dementia among the elderly,
accounting for 60% to 70% of cases. At present, the pathogenesis of this condition remains …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide.
Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase …

Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins
contributing to its etiology. To confront AD, an innovative strategy is to design single …

The therapeutic arsenal for the treatment of Alzheimer's disease (AD) remains confined to a
group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to …

Alzheimer's disease is a complex neurodegenerative disorder with a multifaceted
pathogenesis. This fact has long halted the development of effective anti-Alzheimer drugs …